Institut Pasteur

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

UniversitÉ´de Rouen

Chu De Rouen

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

UniversitÉ Paris Descartes

Universite Paris Cité

Université Paris Diderot

Université Paris Nord

Christine Rouzioux

Luc Montagnier

Solange Chamaret

Francoise Barre-Sinoussi

Francoise Rey

Willy Rozenbaum

Claudine Axler-Blin

Charles Dauguet

Jean-Claude Chermann

Jacqueline Gruest

Robert C Gallo

Mikulas Popovic

Marie-Therese Nugeyre

Pierre Sonigo

Marc Alizon

Francoise Brun-Vezinet

Mangalasseril G Sarngadharan

Denise Guetard

Mireille Guyader

Christine Katlama

Marianne Rey

Francoise Vezinet-Brun

Jacques Gruest, Legal Representative

Francois Brun-Vezinet

Marie-Theresa Nugeyre

Simon Wain-Hobson

Pierre Tiollais

Stewart T Cole

Oliver Danos

Fran&ccedil;ois Clavel

Diane Descamps

François Clavel

Fran&ccedil;oise Brun-Vezinet

Marie Gueudin

Jean-Christophe Plantier

Florence Damond

Francois Clavel

Francedillaois Clavel

Adeline Melard

Mélanie Bertine

Véronique Avettand Fenoel

G Sarngadharan

Françoise Brun-Vezinet

Mangalasseril G Sarngadhar

Francedillaoise Brun-Vezinet

Véronique Avettand-Fenoel

Jean C Chermann

Marie Theresa Nugeyre

Francoise Vezinet-Bruil

The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a primer comprising or consisting of a sequence SEQ ID NO: 5 or a sequence having 90% identity to SEQ ID NO: 5 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 6 or a sequence having at least 90% identity to SEQ ID NO: 6 or the complement of these sequences, and b) determining therefrom the presence or absence and/or the quantity of HIV-2 DNA in the biological sample.

In vitro method for detecting and quantifying HIV-2 DNA

The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of:

In vitro method for the detection and quantification of HIV-2

The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.

HIV-2 antigen compositions

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)

This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA

This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.

Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1

The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.

Retrovirus capable of causing AIDS, means and methods for detecting it in vitro

Method for preparing a viral extract containing HIV-II RNA

The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.

Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1)

Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.

Antibody directed against HIV-1 P25 antigen

Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.

Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies

The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.

Methods and kits for detecting antibodies against an HIV variant

The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.

In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies

Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.

Methods for the preparation of human immunodeficiency virus type 2

Growing community of inventors

Paris, France

Christine Rouzioux